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Introduction
Gastric carcinoma is one of the most common malig-
nancies in the world. In the second half of the 20th cen-
tury, morbidity and mortality rates due to gastric can-
cer showed a sudden increase [1]. Tumour growth is
characterized by dominance of cell proliferation over
cell death, accompanied by a simultaneous suppres-
sion of differentiation. This process occurs  uncontrol-
lably and is harmful to the body, resulting in the for-
mation of incompletely differentiated tissue with a ten-
dency towards continuous extension. Cancer prolifera-
tion is caused by irreversible changes in the cell
genome, leading to dissociation of regulatory and
repair mechanisms. As revealed by recent literature
reports, PI determination may provide prognostically
important information in various types of cancers.
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Abstract: The current study objective was to assess the proliferation indices (PI) of Ki-67, PCNA and MCM2 proteins in
advanced gastric cancer and in metastatic lymph node in correlation with certain clinicopathological features and with post-
operative survival of patients. The study was conducted in a group of 100 patients with advanced gastric cancers. Involve-
ment of local lymph nodes was present in 36 cases. Immunohistochemical investigations were carried out using monoclon-
al antibodies against Ki-67 (DAKO), PCNA (DAKO) and polyclonal antibody to MCM2 (Santa Cruz Biotechnology). Visu-
alization of the antigen/antibody complex was performed using LSAB technique (biotin-streptavidin-peroxidase) followed
by application of chromogene DAB (DAKO). Statistical analysis revealed no correlations of Ki-67, PCNA and MCM2 PI
in tumour tissue or metastatic lymph node with patients' age and gender, tumour location, histological grade, macroscopic
type according to Bormann's classification and histological grading by Lauren's and Goseki's classifications. Moreover, no
correlation was observed of Ki-67 and MCM2 PI in tumour tissue with histological grading.  No correlation was also noted
between the proliferation indices of all the three proteins in the affected lymph node and grade of histological differentia-
tion. Such clinicopathological parameters as patients' age and gender, histological grading by Lauren's and Goseki's classi-
fications and lymph node involvement did not correlate with survival time of patients. Furthermore, no statistically signifi-
cant correlation was shown of postoperative survival time with Ki-67 and MCM2 PI in tumour tissue and metastatic lymph
nodes and with PCNA PI in the affected lymph nodes. However, a statistically significant correlation was found of Ki-67,
PCNA and MCM2 PI in tumour tissue and metastatic lymph nodes with depth of wall invasion and local lymph node
involvement. A statistically significant correlation was also noted between PCNA PI in the main mass of tumour and histo-
logical grading. The postoperative survival time of patients exhibited a statistically significant correlation with tumour loca-
tion and macroscopic type according to Bormann's classification. Correlations on statistical borderline were noted between
survival time and depth of gastric wall invasion and PCNA PI in the main mass of tumour. 
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The most widely used proliferation markers include
Ki-67, PCNA (proliferation cell nuclear antigen) and
MCM2 (minichromosome maintenance protein 2).
The Ki-67 protein was discovered by Gerdes in 1983
as a prototype monoclonal antibody Ki-67. Ki-67
interacts with the nuclear structure present in the
nucleus only in actively proliferating cells, i.e. during
the G1, S and G2 phases of the cell cycle and mitosis.
Non-dividing or "resting" cells in the G0 phase are Ki-
67 antigen negative [2-4]. PCNA is a 36-kDa auxiliary
protein for DNA polymerase δ and ε [5]. The PCNA
protein plays a major role in metabolism of nucleic
acids and has been found to interact with a number of
proteins involved in DNA replication and repair, thus
protecting the DNA sequence pattern [6]. It is synthe-
sized in the cell nucleus and has a key role in cell cycle
initiation. The concentration of PCNA correlates with
cell proliferation – it shows a rise during the G1 phase,
reaches the peak during the G1, S and interphase, falls
during the G2, reaches the low in the M phase, and is
untraceable in cells that are out of the cell cycle [7].
The minichromosome maintenance protein family
(MCM) includes at least six various nuclear proteins
(MCM2-7), showing a striking sequential homology of
200 amino acids in the central region [8]. MCM pro-
teins are essential for DNA replication as part of a pre-
replication complex (pre-RC). The activation of the
MCM complex, through cyclin-dependent kinases and
the Cdc7 (SpHsk1) protein kinase, initiates DNA syn-
thesis [9]. Moreover, the MCM complex has been
found to interact with histone H3 that stabilizes inter-
actions between MCM proteins and chromatin or
affects nucleosome stability in the vicinity of replica-
tion forks [10]. MCM2 protein is absent in cells that
have left the cycle (G0), but is present in proliferating
cells [11]. The study objective was to assess the prolif-
eration indices of Ki-67, PCNA and MCM2 proteins in
advanced gastric cancer and metastatic lymph node in
correlation with certain clinicopathological features
and survival of patients. 
Material and methods 
Collection of samples. The study group consisted of 100 chosen
patients with advanced gastric carcinoma (33 women and 67 men),
operated on in the years 1989-2003. The mean age was 62.5 years
(range 27-83). The patients were clinically monitored for 84
months.
Immunohistochemistry. Formalin-fixed and paraffin-embedded
tissue specimens were cut on a microtome into 5 μm thick sections.
The sections were deparaffinised in xylenes and hydrated in alco-
hols of decreasing concentration. In order to visualise the antigen,
the sections were heated in citrate buffer pH 6.0 (in a pressure
cooker for 3 min. for Ki-67 and PCNA and in a microwave oven,
750W, for 15 min. for MCM2). After cooling to the room temper-
ature, in order to block endogenous peroxidase activity, 10-min
incubation was performed with H2O2. MCM2-positive sections
were incubated with H2O2 and methanol for 15 min., and then with
normal blocking serum (goat ABC Staining System, cat. no sc-
2023, Santa Cruz Biotechnology). After rinsing in TRIS buffer,
pH=7.4, for 10 min, the sections were incubated with antibodies:
Ki-67 (mouse monoclonal antibody, clone MIB-1, cat. no. M7240,
DAKO) in a dilution of 1:100 for 60 min; PCNA (mouse mono-
clonal antibody, clone PC10, cat. no. M0879, DAKO) in a dilution
of 1:400 for 60 min and MCM2 (goat polyclonal antibody, cat. no
sc-9839, Santa Cruz Biotechnology) in a dilution of 1:300
overnight at a room temperature. In the next stage, biotinyl anti-
body was used in the reaction and then the streptavidin-peroxidase
complex (LASB®+ System- HRP, nr kat. K0690, DAKO) was
applied. The antigen-antibody complex was visualized by DAB
chromogen (3'3- diamonobenzidine, cat. no. S3000, DAKO).
Sample assessment. The reactions for Ki-67, PCNA and MCM2
proteins were observed in the cell nucleus. Protein expression was
assessed using a light microscope at a magnification of 60×. The
percentage of protein-positive cells was determined semiquantita-
tively for each 10 fields of vision, as compared to all the cells visi-
ble there. The mean from all the fields of vision was then calculated,
giving the proliferation index expressed in % for each protein.
Next, based on the index, two study groups were isolated in
which nuclear accumulation of Ki-67, PCNA and MCM2 in cancer
cells was determined as either
• negative (-) – lack of reaction for Ki-67, PCNA and MCM2 or
reaction present in <50% of cancer cells, or
• positive (+) – reaction for Ki-67, PCNA and MCM2
present/visible in >50% of cancer cells.
Statistical analysis. Statistical analysis was based on test χ2 and
exact Fisher's test. The p<0.05 was considered statistically signifi-
cant. Multivariate Cox regression analysis was done to evaluate the
5-year overall survival.
Results
Statistical analysis did not show any correlations of
Ki-67, PCNA and MCM2 PI in the main mass of
tumour and metastatic lymph node with age and gen-
der of patients or tumour location in the stomach.
Moreover, no relationship was noted of the protein PI
in tumour tissue and metastatic lymph node with
macroscopic type in Bormann's classification and with
histological type by Lauren's and Goseki's classifica-
tions. Furthermore, the proliferation indices of Ki-67
and MCM2 in tumour tissue and metastatic lymph
node were not found to correlate with the grade of his-
tological differentiation (Tables 1, 2). No correlation
was also found between PCNA PI in metastatic lymph
node and histological grading. A statistically signifi-
cant difference was observed of Ki-67, PCNA and
MCM2 PI in the main mass of tumour with depth of
invasion in the gastric wall (p=0.005; p=0.0005;
p=0.04) (Table 1) and lymph node involvement
(p=0.0000; p=0.000; p=0.000) (Table 1).  The prolifer-
ation index of PCNA in tumour sections was found to
correlate with histological grading  (p=0.05) (Table 1).
Similarly, a statistically significant relationship was
noted of Ki-67, PCNA and MCM2 PI in metastatic
lymph nodes with depth of wall invasion (p=0.0.009;
p=0.00001; p=0.06) (Table 2) and lymph node involve-
ment (p=0.0.0005; p=0.0000; p=0.007) (Table 2).
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Table 1. Correlation between chosen clinico-pathological parameters and proliferation index (PI)  Ki-67, PCNA and MCM2 proteins in
gastric carcinoma. 
*NS – non statistical significence
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Table 2. Correlation between chosen clinico-pathological parameters and proliferation index (PI)  Ki-67, PCNA and MCM2 proteins in
lymph node metastasis
*NS – non statistical significence
Statistical analysis of correlations between survival
time of patients and Ki-67 PI showed a considerably
prolonged survival time in the group of patients with
Ki-67 PI≤50% in the main mass of tumour and in
metastatic lymph node (84 months), as compared to
the patients with Ki-67 PI >50% (61 months). Howev-
er, the correlation was not statistically significant
(p=0.81; p=0.88, respectively) (Fig. 1). The correlation
between survival time and PCNA PI in gastric cancer
was on borderline of statistical significance (p=0.06).
Survival time of patients with PCNA PI in the main
mass of tumour ≤50% was by 23 months longer as
compared to those with PCNA PI >50% (Fig. 2). There
was no statistically significant correlation between
survival time and PCNA index in metastatic lymph
node (p=0.52). Distinct differences, though not statis-
tically significant, were observed in the survival time
between patients with MCM2 index ≤50% (84
months) and >50% (61 months) in the main mass of
tumour (p=0.80) (Fig. 3). In patients with metastatic
lymph node invasion, the mean survival time did not
differ between those with MCM2 ≤50% and >50%
(approximately 60 months; p=0.54).
Discussion
Ki-67 and PCNA have been found to be the most reli-
able markers of cell proliferation. MCM2, a novel
marker, seems to be more sensitive as compared to
other markers long used in routine diagnostics. It is
possible to examine the fraction of growth using a rou-
tine staining technique in order to assess the correla-
tion between cell proliferation and certain pathomor-
phological factors in a large retrospective material.
Similarly to other authors [12-14], we found no corre-
lation between Ki-67, PCNA and MCM2 PI in the
main mass of tumour and certain clinicopathological
parameters (Tables 1, 2). On the other hand, Ki-67 PI
has been reported to be significantly higher in the
intestinal-type cancers by Lauren's classification as
compared to the diffuse type [15,16]. High PCNA PI
has been more frequent in the intestinal than in the dif-
fuse type [17]. Moreover, some authors have shown a
significantly higher proliferation index of Ki-67 in
high-grade tumours as compared to the low-grade ones
[4]. Other clinicopathological factors, including lymph
node involvement and depth of invasion have not been
found to correlate with Ki-67 index [18,19].  Like
other researchers [2,19-23], we found a statistically
significant correlation of Ki-67, PCNA and MCM2 PI
in advanced gastric cancer with local lymph node
involvement. The mean proliferation indices for Ki-67
and PCNA were higher in gastric cancer with local
lymph node involvement.  Thus, the determination of
proliferative activity by means of cell proliferation
markers in gastric carcinomas seems to be useful for
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Fig. 1. Correlation of Ki-67 PI in main mass of tumor with survival
of patients with advanced gastric cancer.
Fig. 2. Correlation of PCNA PI in main mass of tumor with sur-
vival of patients with advanced gastric cancer.
Fig.  3. Correlation of MCM2 PI in main mass of tumor with sur-
vival of patients with advanced gastric cancer.
the prediction of local lymph node involvement
[2,21,22].  Mita et al. [24] revealed a strong correlation
between the proliferative activity of tumour cells and
the presence of metastases to lymph nodes and prog-
nosis in cancers. Moreover, these authors demonstrat-
ed that tumours with high proliferative activity had
high lymph node metastatic potential [24]. Some
authors found no correlation between the proliferation
index of cell proliferation markers and local lymph
node involvement [15,18]. In our study, we revealed a
statistically significant relationship between histologi-
cal grading and PCNA index in the main mass of
tumour.  Irrespective of the grade, the PCNA index
was ≤50% in 60% of the study cases and >50% in
40%. PCNA PI was low mainly in higher-grade
tumours (G2). Our data are consistent with those pub-
lished by Aoyagi et al. [25], who observed a signifi-
cant correlation of PCNA PI with depth of invasion,
histological differentiation and the clinical stadium of
the disease, thus stating that PCNA index is a good
prognostic factor in gastric cancers. Many investiga-
tors have found Ki-67 and PCNA to be prognostic fac-
tors in tumours of the stomach [13-15,22,23,26-29].
Wong et al. [30] showed Ki-67 PI to be an independ-
ent unfavourable prognostic factor in patients with
low-differentiated tumours [13]. Igarashi et al. [31]
reported a significantly higher value of Ki-67 PI in
patients with advanced gastric carcinomas as com-
pared to those with early tumours. The latter group had
a considerably longer survival time than the advanced
cancer patients. The proliferative activity of cancer
cells was found to correlate with metastasis formation
and prognosis. It has been reported that Ki-67 can be
used as a marker of proliferative activity in gastric can-
cer and potential metastases to distant organs [21,22].
High PCNA PI has been usually considered to be a
reliable marker of tumour progression [14]. Patients
with high PCNA PI in early gastric carcinoma much
more frequently have lymph node metastases. More-
over, the postoperative survival time of patients with
high PCNA PI in gastric carcinoma is considerably
shorter than in the case of low PCNA PI in tumour tis-
sue [23,25]. Mûller et al. [15] observed no difference
in the length of postoperative survival between
patients with low and high Ki-67 index. Igarashi et al.
[31] demonstrated that Ki-67 and PCNA PI correlate
with the number of mitoses but are not a reliable prog-
nostic factor in gastric carcinoma. Lee et al. [17] did
not find any prognostic significance of PCNA in this
cancer.  In our study, no correlation was noted between
Ki-67 PI and survival time of advanced gastric carci-
noma patients. The findings indicate a relationship of
Ki-67, PCNA and MCM2 proliferation indices with
such malignancy and progression parameters as depth
of wall invasion and lymph node involvement. More-
over, a correlation was found between PCNA PI and
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Fig. 4. Positive immunostaining of Ki-67 in primary tumor.
Fig. 5. Positive immunostaining of PCNA in primary tumor.
Fig. 6. Positive immunostaining of MCM2 in primary tumor.
histological grade. Worthy of note is that low prolifer-
ative activity, and thus low PCNA PI, indicates more
favourable prognosis and longer survival time in
patients after tumour resection. Literature data con-
cerning MCM2 PI in the alimentary tract carcinomas
suggest that this marker is more sensitive and better for
the assessment of the growth fraction in comparison
with Ki-67 or PCNA [32,33]. Furthermore, high
MCM2 PI in the alimentary tract carcinomas has been
found to indicate more unfavourable prognosis and
higher biological aggressiveness of tumour [32,34].
The postoperative survival time of patients with high
MCM2 PI was significantly shorter as compared to
those with its low index [32]. The data seem to be con-
sistent with the findings obtained for prostate carcino-
ma [35], non-small-cell carcinoma of the lung [36] and
carcinoma of the kidney [37]. We could not find any
literature data concerning correlations between MCM2
PI in gastric carcinomas and pathomorphological
parameters. Our results seem to indicate a correlation
of MCM2 PI in advanced gastric carcinomas with such
parameters of histological malignancy as depth of
invasion and local lymph node involvement. Patients
with low MCM2 PI in the main mass of tumour were
found to live longer as compared to those with high PI.
Thorough investigation into the relationship between
MCM2 PI and respective clinicopathological parame-
ters may allow application of this protein in routine
diagnostics. Assessment of correlations of MCM2
index with other markers, such as Ki-67 or PCNA,
may help determine whether the MCM2 protein is a
more sensitive and reliable marker in the case of
advanced gastric carcinomas. Our results seem to indi-
cate the relationship of Ki-67, PCNA and MCM2 PI
with such parameters of histological malignancy as
depth of wall invasion and lymph node metastases.
However, correlation between the proliferation index
and postoperative survival time was observed only for
PCNA. 
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